223 related articles for article (PubMed ID: 37972659)
21.
Cleary JM; Raghavan S; Wu Q; Li YY; Spurr LF; Gupta HV; Rubinson DA; Fetter IJ; Hornick JL; Nowak JA; Siravegna G; Goyal L; Shi L; Brais LK; Loftus M; Shinagare AB; Abrams TA; Clancy TE; Wang J; Patel AK; Brichory F; Vaslin Chessex A; Sullivan RJ; Keller RB; Denning S; Hill ER; Shapiro GI; Pokorska-Bocci A; Zanna C; Ng K; Schrag D; Jänne PA; Hahn WC; Cherniack AD; Corcoran RB; Meyerson M; Daina A; Zoete V; Bardeesy N; Wolpin BM
Cancer Discov; 2021 Oct; 11(10):2488-2505. PubMed ID: 33926920
[TBL] [Abstract][Full Text] [Related]
22. Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies.
Brandi G; Relli V; Deserti M; Palloni A; Indio V; Astolfi A; Serravalle S; Mattiaccio A; Vasuri F; Malvi D; Deiana C; Pantaleo MA; Cescon M; Rizzo A; Katoh M; Tavolari S
Sci Rep; 2024 Feb; 14(1):3136. PubMed ID: 38326380
[TBL] [Abstract][Full Text] [Related]
23. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
[TBL] [Abstract][Full Text] [Related]
24. FGFR2 Inhibition in Cholangiocarcinoma.
Vogel A; Segatto O; Stenzinger A; Saborowski A
Annu Rev Med; 2023 Jan; 74():293-306. PubMed ID: 36170665
[TBL] [Abstract][Full Text] [Related]
25. The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma.
Ito Y; Yamada D; Kobayashi S; Sasaki K; Iwagami Y; Tomimaru Y; Asaoka T; Noda T; Takahashi H; Shimizu J; Doki Y; Eguchi H
Cancer Lett; 2024 Jul; 595():216997. PubMed ID: 38801887
[TBL] [Abstract][Full Text] [Related]
26. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.
Berchuck JE; Facchinetti F; DiToro DF; Baiev I; Majeed U; Reyes S; Chen C; Zhang K; Sharman R; Uson Junior PLS; Maurer J; Shroff RT; Pritchard CC; Wu MJ; Catenacci DVT; Javle M; Friboulet L; Hollebecque A; Bardeesy N; Zhu AX; Lennerz JK; Tan B; Borad M; Parikh AR; Kiedrowski LA; Kelley RK; Mody K; Juric D; Goyal L
Ann Oncol; 2022 Dec; 33(12):1269-1283. PubMed ID: 36089135
[TBL] [Abstract][Full Text] [Related]
27. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
Cristinziano G; Porru M; Lamberti D; Buglioni S; Rollo F; Amoreo CA; Manni I; Giannarelli D; Cristofoletti C; Russo G; Borad MJ; Grazi GL; Diodoro MG; Giordano S; Sacconi A; Forcato M; Anastasi S; Leonetti C; Segatto O
J Hepatol; 2021 Aug; 75(2):351-362. PubMed ID: 33741397
[TBL] [Abstract][Full Text] [Related]
28. Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma.
Li F; Peiris MN; Donoghue DJ
Cytokine Growth Factor Rev; 2020 Apr; 52():56-67. PubMed ID: 31899106
[TBL] [Abstract][Full Text] [Related]
29. Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management.
Chakrabarti S; Finnes HD; Mahipal A
Expert Opin Drug Metab Toxicol; 2022 Jan; 18(1):85-98. PubMed ID: 35129006
[TBL] [Abstract][Full Text] [Related]
30. Impact of FGFR2 gene fusions on survival of patients with intrahepatic cholangiocarcinoma following curative intent resection.
Buckarma E; De La Cruz G; Truty M; Nagorney D; Cleary S; Kendrick M; Borad M; Graham RP; Gores G; Smoot R
HPB (Oxford); 2022 Oct; 24(10):1748-1756. PubMed ID: 35718679
[TBL] [Abstract][Full Text] [Related]
31. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Aitcheson G; Mahipal A; John BV
Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
[No Abstract] [Full Text] [Related]
32. Identification and In-Depth Analysis of the Novel FGFR2-NDC80 Fusion in a Cholangiocarcinoma Patient: Implication for Therapy.
Scheiter A; Keil F; Lüke F; Grosse J; Verloh N; Opitz S; Schlosser S; Kandulski A; Pukrop T; Dietmaier W; Evert M; Calvisi DF; Utpatel K
Curr Oncol; 2021 Mar; 28(2):1161-1169. PubMed ID: 33800328
[TBL] [Abstract][Full Text] [Related]
33. The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma.
Spahn S; Kleinhenz F; Shevchenko E; Stahl A; Rasen Y; Geisler C; Ruhm K; Klaumuenzer M; Kronenberger T; Laufer SA; Sundberg-Malek H; Bui KC; Horger M; Biskup S; Schulze-Osthoff K; Templin M; Malek NP; Poso A; Bitzer M
Nat Commun; 2024 Feb; 15(1):1287. PubMed ID: 38346946
[TBL] [Abstract][Full Text] [Related]
34. Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M; King G; Spencer K; Borad MJ
Oncologist; 2023 Nov; 28(11):928-943. PubMed ID: 37390492
[TBL] [Abstract][Full Text] [Related]
35. Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in
Sase H; Nakanishi Y; Aida S; Horiguchi-Takei K; Akiyama N; Fujii T; Sakata K; Mio T; Aoki M; Ishii N
Mol Cancer Ther; 2018 Oct; 17(10):2217-2225. PubMed ID: 30045926
[No Abstract] [Full Text] [Related]
36. FGF10/FGFR2 Signaling: Therapeutically Targetable Vulnerability in Ligand-responsive Cholangiocarcinoma Cells.
Oeurn K; Jusakul A; Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Kongpetch S
In Vivo; 2023; 37(4):1628-1637. PubMed ID: 37369494
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
[TBL] [Abstract][Full Text] [Related]
38. FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures.
Sridharan V; Neyaz A; Chogule A; Baiev I; Reyes S; Barr Fritcher EG; Lennerz JK; Sukov W; Kipp B; Ting DT; Deshpande V; Goyal L
Clin Cancer Res; 2022 Dec; 28(24):5431-5439. PubMed ID: 36190545
[TBL] [Abstract][Full Text] [Related]
39. FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience.
Gile JJ; Ou FS; Mahipal A; Larson JJ; Mody K; Jin Z; Hubbard J; Halfdanarson T; Alberts SR; Jatoi A; McWilliams RR; Ma WW; Ilyas S; Smoot R; Roberts L; Gores G; Borad M; Bekaii-Saab TS; Tran NH
JCO Precis Oncol; 2021; 5():. PubMed ID: 34778691
[TBL] [Abstract][Full Text] [Related]
40. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy.
Krook MA; Bonneville R; Chen HZ; Reeser JW; Wing MR; Martin DM; Smith AM; Dao T; Samorodnitsky E; Paruchuri A; Miya J; Baker KR; Yu L; Timmers C; Dittmar K; Freud AG; Allenby P; Roychowdhury S
Cold Spring Harb Mol Case Stud; 2019 Aug; 5(4):. PubMed ID: 31371345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
